Sarepta Resumes Elevidys Shipments After FDA Safety Review

Resumption of Elevidys Shipments

• 🚀 Sarepta Therapeutics is resuming shipments of its gene therapy, Elevidys, to patients who can walk.
• ⚠️ This follows a temporary pause recommended by the FDA due to serious safety concerns, including patient deaths.

FDA Safety Review and Patient Deaths

• 📉 Last week, the FDA recommended a pause after three patient deaths among those on Sarepta therapies.
• ✅ The FDA has since stated that a recent child's death was unrelated to the gene therapy.
• 🎯 Sarepta's CEO is working with the FDA to update the safety label and discuss risk mitigation for non-ambulatory patients.

Regulatory and Market Context

• 📈 Despite the resumption of shipments, Sarepta's stock is still down significantly year-to-year.
• 🏛️ The FDA's Center for Biologics Evaluation and Research, led by Dr. Vinnie Prasad, had initially pushed for a complete halt in shipments.
• 🗣️ The FDA's decision to allow shipments to ambulatory patients faced pushback from patient families, who rely on Elevidys as their only available therapy.
• 📰 An op-ed in The Wall Street Journal criticized the FDA's actions as potentially hindering drug innovation, sparking debate from both political sides.